Clinical trial of the auxiliary treatment with Gui Qi Bai Zhu fang in the treatment of patients with gastric cancer归芪白术方胃癌血清肿瘤标志物免疫炎性因子Kamofsky评分目的 观察归芪白术方辅助治疗胃癌患者的临床研究.方法 选择甘肃省武威肿瘤医院就诊的50例胃癌患者,随机分为对照组和试验组各...
(A) Cases that have an important clinical impact: 1) Remarkable effects of a new therapy for gastric cancer; 2) Previously unreported adverse events in treatments for gastric cancer; 3) Novel suggestions or pitfalls in diagnosing gastric cancer; (B) Cases that may provide significant clues to ...
Pluchino, PhD NCCN Guidelines Panel Disclosures Continue Clinical Trials: NCCN believes that the best management for any patient with cancer is in a Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is ...
基本信息: 期刊简称:GASTRIC CANCER 是否OA:未开放 是否预警:否 Gold OA文章占比:34.55% 出版信息: 出版地区:JAPAN 出版周期:Quarterly 出版语言:English 出版商:Springer Singapore 评价信息: 中科院分区:1区 JCR分区:Q1 影响因子:6 CiteScore:14.7 投稿咨询 加急咨询 ...
Intercepting gastric cancer Pan et al. performed a large-scale, cluster-randomized controlled trial to assess whether eradicatingHelicobacter pyloriin asymptomatic individuals would be beneficial in preventing gastric cancer. Anna Dart Research Highlights05 Sept 2024Nature Reviews Cancer ...
These data support the approval of pembro plus trastuzumab and chemo in pts with HER2+ mG/GEJ cancer and confirm this regimen as SOC in the first-line setting. Clinical trial identification NCT03615326. 1401O - Trastuzumab...
Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. This study was designed as a prospective, randomized clinical trial with a total of 59 patients. Twenty-nine (49.1%) patients were randomized to undergo... CG Huscher,A ...
1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,open-label, randomised controlled trial[J]. Lancet, 2010,376(9742):...
Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict. Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype (MP) and epithelial phenotype (EP), by analyzing genomic and proteomic data. M
There is an abundance of ongoing clinical trials exploring a variety of pharmacologic agents for treating gastric cancer. Pharmacists play an integral role in collaborating with physicians to manage gastric cancer therapy. Through this multidisciplinary alliance, pharmacists enhance the prospects for favorabl...